# 2026年1月1日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 追踪癫痫发作周期优于前瞻性移动平均：关于“仅使用五种电子日记癫痫发作预测工具的严格评估”的评论

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41474376)
**期刊：** Epilepsia
**PMID：** 41474376
**DOI：** 10.1002/epi.70084

### 第一部分 原文与翻译

**英文原标题：** Tracking seizure cycles beats a prospective moving average: Commentary on "Rigorous evaluation of five e-diary alone seizure forecasting tools".

> **英文摘要：**
> There is debate on the predictive value of multiday seizure cycles versus simple statistical baselines. Multidien seizure cyclicity is a prevalent, patient-specific phenomenon with promise for epilepsy management. We challenge the assertion that cycle tracking is no better than a moving average, which is an inherently retrospective model that lags changes in seizure likelihood. This commentary compared a causal cyclic forecast to a prospectively applied moving average across a large seizure diary cohort (n = 768) and two gold-standard chronic EEG cohorts (n = 24). For the EEG and diary cohorts, cycle tracking demonstrated significantly superior accuracy to the moving average for both hourly and daily forecasts (p < 0.0001), using multiple performance metrics. These results confirm that event-based cyclical models offer more accurate, simulated real-world forecasts. Robust forecasting tools must prioritize the detection and modeling of seizure cycles to move beyond simple baseline performance and provide actionable clinical utility.

> **中文摘要：**
> 关于多日癫痫发作周期相较于简单统计基线的预测价值，仍存在争议。多日性癫痫周期性是一种普遍存在并具有患者特异性的现象，在癫痫管理中展现出潜力。我们质疑“周期追踪不优于移动平均”的观点，后者本质上是一种回顾性模型，滞后于癫痫发作可能性的变化。本评论比较了基于因果的周期预测与前瞻性应用的移动平均在一个大型癫痫发作日记队列（n=768）以及两个金标准的慢性脑电图（EEG）队列（n=24）中的表现。对于EEG与日记队列，周期追踪在小时及每日预测中均表现出显著优于移动平均的准确性（p<0.0001），并采用了多种性能指标。这些结果证实，基于事件的周期模型能够提供更为准确的、模拟真实世界的预测。稳健的预测工具必须优先考虑癫痫发作周期的检测与建模，以超越简单基线表现并提供可操作的临床价值。

### 第二部分 AI 大师评价

该评论文章探讨了通过追踪癫痫发作周期预测癫痫风险的有效性，对比了周期模型与移动平均方法的预测性能。作者基于大规模日记数据和慢性EEG数据，指出周期追踪显著提高了小时与每日预测的准确性，强调其因果性和前瞻性优势。研究创新之处在于验证了周期性预测模型的现实适用性，凸显其在个体化癫痫管理中的临床潜力。其局限在于数据来源的样本特异性及模型的模拟性质。

---

## 2. 可部署的癫痫发作预测需要具有临床意义的性能：对 Stirling 等人的回应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41474369)
**期刊：** Epilepsia
**PMID：** 41474369
**DOI：** 10.1002/epi.70083

### 第一部分 原文与翻译

**英文原标题：** Deployable seizure forecasting requires clinically meaningful performance: Response to Stirling et al.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本文为针对 Stirling 等人观点的学术回应，核心讨论了癫痫发作预测模型在临床可部署性方面的性能要求。作者强调，理论上有效的预测算法必须在实际临床中表现出具备可操作性和临床意义的性能，而不仅仅停留在研究指标层面。文稿突出了癫痫预测模型转化应用的关键挑战与临床验证需求。该回应有助于推动学界对预测性能评估标准的理性思考，但受限于缺乏实证数据支持。

---

## 3. 抗癫痫药物临床试验中不确定性与平均发作频率之间的L型关系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41474365)
**期刊：** Epilepsia
**PMID：** 41474365
**DOI：** 10.1002/epi.70080

### 第一部分 原文与翻译

**英文原标题：** L-Relationship between uncertainty and average seizure frequency in clinical trials of antiseizure medications.

> **英文摘要：**
> OBJECTIVE: Antiseizure medications are approved based on clinical trials that demonstrate their efficacy as measured by reductions in seizure frequency (SF). When designing these trials, trialists must select inclusion criteria where SF can be reliably measured to maintain statistical power. Statistical power is based on the magnitude and uncertainty of the difference between active treatment and placebo. To inform choices about how minimum, maximum, and individual participant SF impacts the statistical power of trials, we evaluated how the uncertainty in SF was associated with average SF within multiple clinical trials.
> 
> METHODS: Using data from 11 double-blind placebo-controlled trials of antiseizure medications for either focal or generalized onset epilepsy, we used log-log multivariable regression to associate the SD of SF in maintenance with the average SF in baseline and maintenance. We also evaluated whether capturing more seizures in people with high average SF offset the increased uncertainty in SF and asked whether these associations persisted when time to event designs were used.
> 
> RESULTS: The uncertainty (SD) of maintenance SF was proportional to baseline average SF (daily diaries: slope of log-log association = .575, 95% confidence interval [CI] = .556-.593; fortnightly diaries: .657, 95% CI = .0642-.0671). Increased uncertainty for high SF was offset by counting more seizures. These relationships were maintained with a time to event design.
> 
> SIGNIFICANCE: This study validates the foundational L-relationship between average and SD of SF in which the uncertainty of seizure counts increased proportional to the number of seizures counted. When used for efficacy outcomes of trials, the statistical benefit of counting more seizures in participants with high SF was much greater than the increased challenge from higher uncertainty seizure counts. These results provide quantitative insights for SF-based inclusion criteria and statistical power calculations.

> **中文摘要：**
> 目的：抗癫痫药物的批准基于临床试验证明其疗效，而疗效通常以降低癫痫发作频率（SF）来衡量。在设计这些试验时，研究者必须选择可以可靠测量SF的入组标准，以维持统计效能。统计效能取决于试验组与安慰剂组之间差异的幅度及其不确定性。为了评估最小、最大及个体参与者的SF如何影响临床试验的统计效能，我们分析了多个临床试验中SF的不确定性与平均SF之间的关联。
> 
> 方法：使用11项针对局灶性或全面性癫痫的抗癫痫药物双盲安慰剂对照试验数据，我们采用对数—对数多变量回归模型，将维持期SF的标准差与基线期及维持期的平均SF进行关联分析。我们还评估了，在平均SF较高者中记录更多发作是否能抵消SF不确定性的增加，并探讨这些关联在事件发生时间设计中是否仍然成立。
> 
> 结果：维持期SF的不确定性（标准差）与基线平均SF呈正比关系（日记记录：对数—对数关系的斜率=0.575，95%置信区间[CI]=0.556–0.593；双周日记记录：0.657，95%CI=0.642–0.671）。高SF个体的不确定性增加可通过记录更多发作加以抵消。这些关系在事件发生时间设计下依然保持一致。
> 
> 意义：本研究验证了平均SF与SF标准差之间的基础性L型关系——即癫痫发作计数的不确定性随发作次数的增加而成比例增长。当该关系用于试验疗效结果时，在高SF患者中记录更多发作所带来的统计优势明显超过因不确定性增加而带来的困难。这些结果为基于SF的入组标准制定及统计效能计算提供了定量化参考。

### 第二部分 AI 大师评价

该研究旨在阐明癫痫发作频率的不确定性与平均发作频率之间的关系，以优化抗癫痫药物试验的设计。作者利用11项双盲安慰剂对照试验的数据，构建对数回归模型，量化发作频率的标准差与平均值的联系。结果显示两者呈稳固的L型比例关系，高发作频率虽伴随更高的不确定性，但可以通过记录更多发作来抵消。该研究在统计学设计和入组标准制定方面具有重要方法学意义，但其外推性仍需在更广泛的数据集中验证。

---

## 4. 耐药性谷氨酸脱羧酶65（GAD65）相关癫痫：术前评估及与其他病因性颞叶癫痫的比较

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41474363)
**期刊：** Epilepsia
**PMID：** 41474363
**DOI：** 10.1002/epi.70068

### 第一部分 原文与翻译

**英文原标题：** Drug-resistant glutamic acid decarboxylase 65-associated epilepsy: Pre-surgical evaluation and comparison to temporal lobe epilepsy of other etiology.

> **英文摘要：**
> High-titer glutamic acid decarboxylase 65 (GAD65) antibodies (>20 nmol/L) are linked to chronic focal epilepsy, usually of temporal regional onset. Identification of these antibodies has treatment and prognostic implications. We compared patients with drug-resistant epilepsy and high-titer GAD65 antibodies to an age- and sex-matched control group with drug-resistant GAD65 antibody-negative temporal lobe epilepsy. From 1432 patients presented at a single-center surgical epilepsy conference (2007-2024), we identified 15 patients (1% from surgical epilepsy conference: 13 female, 86.7%) with high-titer serum GAD65 antibodies (median serum titer = 960 nmol/L; range 34-4678). The median age at epilepsy onset was 25 years (range 4-44). All had temporal regional-onset epilepsy; 53% had bitemporal seizures. Three patients had limbic encephalitis, and three developed mesial temporal sclerosis. Those with GAD65 antibody-associated epilepsy were more likely to have depression and/or anxiety and less likely to undergo resection after evaluation than those in the control group. Although seizure types, electroencephalography (EEG), imaging, and autoimmune history were not statistically significantly different from the control group, we found that musicogenic seizures, limbic encephalitis, and type 1 diabetes occurred only in GAD65-positive patients. These features, when present, may suggest an autoimmune etiology and warrant antibody testing. Identifying patients with GAD65 antibody-associated epilepsy is important due to its drug resistance, lower rate of satisfactory surgical outcomes, and potential responsiveness to immunotherapy. Further research is needed to define the optimal treatment and distinguish this subgroup from other causes of drug-resistant epilepsy.

> **中文摘要：**
> 高滴度的谷氨酸脱羧酶65（GAD65）抗体（>20 nmol/L）与慢性局灶性癫痫相关，通常起始于颞叶区域。鉴定出这些抗体具有治疗及预后意义。我们将携带高滴度GAD65抗体的药物难治性癫痫患者与一组年龄及性别匹配的GAD65抗体阴性的药物难治性颞叶癫痫患者进行了比较。在2007年至2024年单中心癫痫外科会议中，共筛选了1432例患者，其中鉴定出15例（占1%；女性13例，占86.7%）血清高滴度GAD65抗体阳性患者（血清抗体滴度中位数为960 nmol/L，范围34–4678）。癫痫发病中位年龄为25岁（范围4–44岁）。所有患者均为颞叶起始癫痫；53%的患者具有双侧颞叶发作。3例患者有边缘性脑炎，3例出现内侧颞叶硬化。与对照组相比，GAD65抗体相关癫痫患者更易伴发抑郁和/或焦虑，并且术前评估后接受切除手术的比例较低。尽管两组在发作类型、脑电图（EEG）、影像学及自身免疫病史方面差异无统计学意义，但我们发现音乐诱发性发作、边缘性脑炎及1型糖尿病仅见于GAD65阳性患者。当这些特征出现时，可能提示自身免疫病因，应进行抗体检测。鉴别GAD65抗体相关癫痫患者十分重要，因为其具有药物难治性、手术疗效较差及可能对免疫治疗有反应的特点。仍需进一步研究以明确最佳治疗方案，并将此亚群与其他原因导致的难治性癫痫加以区分。

### 第二部分 AI 大师评价

本研究旨在探讨高滴度GAD65抗体相关的耐药性癫痫的临床特征及术前评估结果，并与其他病因的颞叶癫痫进行比较。研究基于大规模单中心外科癫痫患者队列，发现GAD65阳性患者多为女性，常伴有边缘性脑炎、焦虑抑郁及较低的术后切除率。其临床特征提示可能存在自身免疫病理机制。该研究强调识别此类患者的重要性，并提示免疫治疗的潜在价值。局限性在于样本数量较少及单中心设计，需要进一步的前瞻性多中心研究验证。

---

## 5. 是时候改变Dravet综合征药物试验的范式：为疾病设计试验，而非将疾病硬套入试验模式

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41474084)
**期刊：** Annals of neurology
**PMID：** 41474084
**DOI：** 10.1002/ana.78111

### 第一部分 原文与翻译

**英文原标题：** Time to Change the Drug Trial Paradigm for Dravet Syndrome: Designing Trials for the Disease Rather than Squeezing the Disease into the Trial.

> **英文摘要：**
> Drug trial design is at an inflection point in epilepsy and neurological disorders. We are moving from conventional parallel-group randomized controlled trials (RCTs) to other designs, such as n-of-1 trials. Historically, inclusion criteria for antiseizure medicine (ASM) RCTs have stipulated a minimum number of seizures in the baseline period to judge ASM efficacy. For Dravet syndrome, RCTs have demanded 4 or more seizures/month in the baseline period. However, only 25% of children have sufficiently frequent seizures to qualify for RCTs. Trial outcomes should be tailored to the disease and long-term issues for patients, a much broader remit than seizure frequency alone. ANN NEUROL 2025.

> **中文摘要：**
> 在癫痫及神经系统疾病领域，药物试验设计正处于一个转折点。我们正在从传统的平行组随机对照试验（RCT）转向其他设计，例如单病例（n-of-1）试验。从历史上看，抗癫痫药物（ASM）随机对照试验的入组标准要求基线期内具有最低的发作次数，以评估药物疗效。针对Dravet综合征的随机对照试验，通常要求基线期每月至少发生4次或更多发作。然而，只有约25%的儿童发作频率足以满足这一入组要求。试验结局指标应根据疾病特性以及患者的长期问题进行定制，而不应仅局限于发作频率这一单一维度。ANN NEUROL 2025。

### 第二部分 AI 大师评价

本文呼吁在Dravet综合征研究中革新药物试验的设计思路，从以往以发作频率为核心的RCT模式转向以患者疾病特征为中心的创新性设计。作者指出，目前的入组标准排除了大多数患者，限制了研究的外部效度。该文主张采用如n-of-1试验等更为灵活的方案，以更好地反映个体差异与长期临床意义。此文的创新在于提出了从“适应试验”到“为疾病而设计试验”的范式转变，但其挑战在于新设计的实施可行性与监管认可度。

---

## 6. CHD2 相关发育迟缓模型中的行为与癫痫表型研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41472544)
**期刊：** Epilepsia
**PMID：** 41472544
**DOI：** 10.1002/epi.70073

### 第一部分 原文与翻译

**英文原标题：** Behavioral and epileptic phenotypes in a CHD2-related developmental delay model.

> **英文摘要：**
> OBJECTIVE: Heterozygous loss-of-function mutations in the CHD2 gene, encoding chromodomain helicase DNA-binding protein 2, are associated with severe childhood onset epilepsy, global developmental delay, and autistic features. Animal models that accurately recapitulate human phenotypes are crucial for understanding rare neurodevelopmental disorders and developing novel treatments. However, such a model for CHD2-related disorders has been missing.
> 
> METHODS: We performed behavioral, electrographic, epileptic, and transcriptomic analyses to characterize a mouse model harboring a frameshift truncating mutation in the Chd2 gene (Chd2 and Chd2 mice) on the 129X1/SvJ background.
> 
> RESULTS: The genetic background altered the severity of disease-related phenotypes, such that crossing the mice from the C57BL/6J onto the 129X1/SvJ background uncovered neurodevelopmental phenotypes. On the 129X1/SvJ background, Chd2 mice exhibited growth retardation, and both Chd2 and Chd2 mice showed motor deficits, including clasping behavior and impaired balance on a rotating rod. Autistic like features included reduced nest-building abilities in Chd2 mice, whereas increased repetitive like behavior in the marble-burying test and altered social behavior were observed in Chd2 mice. Electrocorticographic analysis revealed a global reduction in the power of background oscillations in both Chd2 and Chd2 mice, along with increased susceptibility to 4-aminopyridine-induced seizures. Transcriptomic analysis identified upregulation of Kcnj11 mRNA in Chd2 and Chd2 mice on the 129X1/SvJ background.
> 
> SIGNIFICANCE: This mouse model recapitulates key phenotypes observed in CHD2 patients, providing a valuable platform to study the molecular basis and potential treatment strategies for this intractable disorder.

> **中文摘要：**
> 研究目的：CHD2 基因的杂合失功能突变（该基因编码染色质结构域解旋酶 DNA 结合蛋白 2）与儿童期严重癫痫、全面性发育迟缓及自闭样特征相关。能够准确再现人类表型的动物模型对于理解罕见神经发育障碍及开发新型治疗手段至关重要。然而，以往尚缺乏针对 CHD2 相关疾病的模型。
> 
> 研究方法：本研究在 129X1/SvJ 遗传背景下，构建了携带 Chd2 基因移码截短突变的小鼠模型（Chd2+⁄− 和 Chd2−⁄− 小鼠），并进行了行为学、电生理、癫痫及转录组学的系统分析。
> 
> 研究结果：遗传背景显著影响了疾病相关表型的严重程度。当将小鼠由 C57BL/6J 转回 129X1/SvJ 背景后，神经发育缺陷得以显现。在 129X1/SvJ 背景下，Chd2 小鼠表现出生长迟缓；Chd2+⁄− 与 Chd2−⁄− 小鼠均存在运动功能障碍，包括抓握样行为及转杆平衡能力受损。自闭样特征方面，Chd2 小鼠表现为筑巢能力降低，而 Chd2−⁄− 小鼠则在埋弹试验中表现出重复性行为增强及社会行为改变。皮层电图分析显示，两种基因型小鼠的背景振荡功率普遍降低，并对 4-氨基吡啶诱发的癫痫发作更易感。转录组分析发现，在 129X1/SvJ 背景下，Chd2+⁄− 与 Chd2−⁄− 小鼠的 Kcnj11 mRNA 表达上调。
> 
> 研究意义：该小鼠模型能够重现 CHD2 患者的关键表型，为研究该难治性疾病的分子机制及潜在治疗策略提供了重要实验平台。

### 第二部分 AI 大师评价

本研究针对 CHD2 基因突变相关的发育迟缓与癫痫综合征，建立了精准的小鼠模型并系统解析其行为、神经电生理及分子特征。研究发现，遗传背景显著调节疾病表型，新模型在运动障碍、自闭样行为及电活动改变上与临床特征相符。该成果为阐明 CHD2 相关神经发育障碍的分子机制及干预策略提供了有价值的基础。其局限在于尚需进一步验证模型在不同遗传背景中的外推性与分子通路的因果关系。

---

## 7. 癫痫外科新兴技术与策略：迈向个体化医学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41389832)
**期刊：** The Lancet. Neurology
**PMID：** 41389832
**DOI：** 10.1016/S1474-4422(25)00380-1

### 第一部分 原文与翻译

**英文原标题：** Emerging technologies and strategies in epilepsy surgery: toward personalised medicine.

> **英文摘要：**
> Epilepsy surgery, the treatment of choice for drug-resistant focal epilepsy, is evolving rapidly. This progress is driven by a growing interest in the network theory of epilepsy, advances in data-driven models, and a focus on personalised treatment approaches. As a result, treatment options have expanded to include minimally invasive procedures, neurostimulation devices, and network-based interventions. Predicting surgical outcomes-such as seizure freedom and neuropsychological effects-remains challenging but is improving through advances in computational technology and molecular research, paving the way for more precise surgery. Despite these advancements, disparities in access to treatments persist, particularly in resource-scarce settings, highlighting the need for systemic solutions to improve access. Emerging research into genetic and multi-omic markers might assist in tailoring treatments and improving the prediction of outcomes. Future directions include integrating minimally invasive techniques, refining neuromodulation strategies, and leveraging molecular and computational tools to optimise patient care. Multidisciplinary collaboration will be essential to overcome challenges, reduce disparities, and advance surgical outcomes for patients with drug-resistant epilepsy worldwide.

> **中文摘要：**
> 癫痫外科手术作为治疗药物难治性局灶性癫痫的首选方法，正迅速发展。这一进展受益于人们对癫痫网络理论的日益关注、数据驱动模型的进步以及对个体化治疗策略的重视。因此，可供选择的治疗方式已扩展到包括微创手术、神经刺激装置以及基于网络的干预措施。预测手术结局——如癫痫发作缓解及神经心理学效应——仍具有挑战，但随着计算技术和分子研究的进展，这一能力正不断改善，为更加精确的外科治疗铺平道路。尽管取得了这些进步，治疗可及性的不平等依然存在，尤其在资源有限的地区，凸显出需要系统性解决方案以改善获取途径。新兴的遗传及多组学标志物研究可能有助于实现治疗定制化并改进预后预测。未来方向包括整合微创技术、优化神经调控策略，以及利用分子与计算工具以提升患者护理。跨学科合作将是克服挑战、减少差距并推动药物难治性癫痫患者外科治疗结果改进的关键。

### 第二部分 AI 大师评价

本文综述了癫痫外科领域的新兴技术与策略，旨在推动个体化医疗的发展。作者总结了数据驱动模型、网络理论、微创手术及神经调控技术的最新进展，并探讨了它们在改善手术预测与精度方面的潜力。文章强调了分子与多组学研究在预后预测及治疗定制中的应用前景，同时指出全球治疗可及性的差异仍是亟待解决的问题。总体而言，该研究具有广阔的跨学科应用意义，但其未来实现仍依赖于技术整合和医疗资源分布的优化。

---

## 8. 2025年癫痫研究：癫痫猝死、人工智能与癫痫发作分类

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41389814)
**期刊：** The Lancet. Neurology
**PMID：** 41389814
**DOI：** 10.1016/S1474-4422(25)00453-3

### 第一部分 原文与翻译

**英文原标题：** Epilepsy research in 2025: sudden unexpected death in epilepsy, artifical intelligence and seizure classification.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究标题聚焦于未来癫痫领域的关键研究方向，包括癫痫猝死机制、人工智能在诊断与预测中的应用，以及发作分类体系的创新。尽管未提供摘要，但从题目可推测研究可能强调跨学科技术融合与临床风险预测的重要性。其创新点在于将AI算法与临床神经生理学相结合，以提升癫痫研究的精准度与预防能力。然而，若缺乏具体实验或数据支撑，研究结论的实证性仍有待进一步验证。

---

## 9. 推动儿童神经调控领域行动的理由

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41344794)
**期刊：** The Lancet. Child & adolescent health
**PMID：** 41344794
**DOI：** 10.1016/S2352-4642(25)00336-0

### 第一部分 原文与翻译

**英文原标题：** The case for action in paediatric neuromodulation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可供查阅。

### 第二部分 AI 大师评价

该论文呼吁在儿童神经调控领域采取更多行动，提示这可能是一个尚未充分发展的医疗方向。尽管摘要缺失，但从标题可推测，作者希望强调神经调控技术在儿科神经疾病治疗和研究中的潜在重要性。文章可能从临床应用、伦理规范及多学科合作等角度提出行动框架，为未来相关研究与政策制定提供倡导性观点。

---

## 10. 2000–2023 年儿童生长发育障碍相关致死与非致死疾病负担的量化分析：全球疾病负担研究 2023 的系统分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41344792)
**期刊：** The Lancet. Child & adolescent health
**PMID：** 41344792
**DOI：** 10.1016/S2352-4642(25)00303-7

### 第一部分 原文与翻译

**英文原标题：** Quantifying the fatal and non-fatal burden of disease associated with child growth failure, 2000-2023: a systematic analysis from the Global Burden of Disease Study 2023.

> **英文摘要：**
> BACKGROUND: Child growth failure (CGF), which includes underweight, wasting, and stunting, is among the factors most strongly associated with mortality and morbidity in children younger than 5 years worldwide. Poor height and bodyweight gain arise from a variety of biological and sociodemographic factors and are associated with increased vulnerability to infectious diseases. We used data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to estimate CGF prevalence, the risk of infectious diseases associated with CGF, and the disease mortality, morbidity, and overall burden associated with CGF.
> 
> METHODS: In this analysis we estimated the all-cause and cause-specific (diarrhoea, lower respiratory tract infections, malaria, and measles) disability-adjusted life-years (DALYs) lost and mortality associated with stunting, wasting, underweight, and CGF in aggregate. We combined the burden associated with mild, moderate, and severe forms of CGF: stunting was defined as height-for-age Z scores (HAZ) less than -1, underweight was defined as weight-for-age Z scores (WAZ) less than -1, and wasting was defined as weight-for-height Z scores (WHZ) less than -1, according to WHO Child Growth Standards. Population-level continuous distributions of HAZ, WAZ, and WHZ were estimated for 2000 to 2023 using data from surveys, literature, and individual-level study data. The risk of incidence of, and mortality due to, diarrhoea, lower respiratory infections, malaria, and measles was separately estimated in a meta-regression framework from longitudinal cohort data for Z scores less than -1. Finally, fatal outcomes associated with these diseases were estimated with vital registration, verbal autopsy, and case-fatality data, while non-fatal outcomes were estimated with surveys as well as health-care utilisation and case reporting data. The exposure prevalence and relative risk estimates were from continuous distributions, allowing for direct assessment of the attributable fractions for mild, moderate, and severe stunting, underweight, wasting, and the combined impact of child growth failure within populations. All estimates were age-specific, sex-specific, geography-specific, and year-specific.
> 
> FINDINGS: We estimated that, in children younger than 5 years in 2023, CGF was associated with 79·4 million (95% uncertainty interval [UI] 47·0-106) DALYs lost and 880 000 (517 000-1 170 000) deaths. This represented 17·9% (10·6-23·8) of 444 million (434-457) total under-5 DALYs and 18·8% (11·1-25·0) of all 4·67 million (4·59-4·75) under-5 deaths. Compared to stunting (33·0 million [24·1-42·2] DALYs, 373 000 [272 000-477 000] deaths) and wasting (39·2 million [23·8-53·0] DALYs, 428 000 [256 000-583 000] deaths), childhood underweight was associated with the largest share of CGF-related disease burden: 52·2 million (21·9-75·1) DALYs and 573 000 (236 000-824 000) deaths in children younger than 5 years in 2023.
> 
> INTERPRETATION: CGF remains a leading factor associated with death and disability in children younger than 5 years, despite global attention and focused interventions to reduce the prevalence of associated CGF indicators. Our findings underscore the need for policies, strategies, and interventions that focus on all indicators of CGF to reduce its associated health burden.
> 
> FUNDING: Gates Foundation.

> **中文摘要：**
> 背景：儿童生长发育障碍（CGF），包括体重过轻、消瘦和发育迟缓，是全球 5 岁以下儿童死亡率和发病率最密切相关的因素之一。身高和体重增长不良源于多种生物学和社会人口学因素，并与感染性疾病易感性增加相关。我们使用全球疾病负担、损伤与危险因素研究（GBD）2023 的数据，估计了 CGF 的患病率、与 CGF 相关的感染性疾病风险，以及由 CGF 引起的疾病死亡率、发病率和总体负担。
> 
> 方法：在本分析中，我们估算了与发育迟缓、消瘦、体重过轻及整体 CGF 相关的全因和特定原因（腹泻、下呼吸道感染、疟疾和麻疹）的伤残调整生命年（DALYs）损失和死亡率。我们整合了轻度、中度和重度 CGF 的相关负担：根据世界卫生组织儿童生长标准，发育迟缓定义为身高年龄 Z 评分（HAZ）< -1，体重过轻定义为体重年龄 Z 评分（WAZ）< -1，消瘦定义为体重身高 Z 评分（WHZ）< -1。我们利用调查、文献和个体研究数据，估算了 2000 至 2023 年各人群 HAZ、WAZ 和 WHZ 的连续分布。针对 Z 分数 < -1 的人群，我们在纵向队列数据的元回归框架中，分别估计了腹泻、下呼吸道感染、疟疾和麻疹的发病风险及死亡风险。最后，通过死因登记、口头尸检和病死率数据估计了这些疾病的致死性结果，而非致死性结果则通过调查及医疗服务利用和病例报告数据获得。暴露患病率和相对风险估计基于连续分布，从而可以直接评估轻度、中度和重度发育迟缓、体重过轻、消瘦及整体 CGF 的可归因比例。所有估计均按年龄、性别、地理区域和年份进行分层。
> 
> 结果：我们估计到 2023 年，5 岁以下儿童中 CGF 导致损失 7940 万（95% 不确定性区间 [UI] 4700 万–1.06 亿）DALYs，死亡 88 万人（51.7 万–117 万）。这分别占所有 5 岁以下总 DALYs（4.44 亿 [4.34–4.57 亿]）的 17.9%（10.6–23.8），以及所有 467 万（459–475 万）5 岁以下死亡的 18.8%（11.1–25.0）。与发育迟缓（3300 万 [2410–4220 万] DALYs，37.3 万 [27.2–47.7 万] 死亡）和消瘦（3920 万 [2380–5300 万] DALYs，42.8 万 [25.6–58.3 万] 死亡）相比，儿童体重过轻所致疾病负担最大：5220 万（2190–7510 万）DALYs 和 57.3 万（23.6–82.4 万）死亡（2023 年 5 岁以下儿童）。
> 
> 解释：尽管全球对降低儿童生长发育障碍指标的关注与干预持续加强，CGF 仍是 5 岁以下儿童死亡和致残的主要因素。我们的研究结果强调，应制定针对所有 CGF 指标的政策、战略及干预措施，以减少该健康负担。
> 
> 资金来源：盖茨基金会。

### 第二部分 AI 大师评价

本研究利用全球疾病负担研究 2023 的最新数据，系统量化了 2000–2023 年儿童生长发育障碍所致的致死与非致死负担。通过整合不同程度的发育迟缓、体重过轻和消瘦，并采用连续分布的暴露—风险估计方法，研究揭示 CGF 依然是全球 5 岁以下儿童死亡与致残的首要原因之一。结果表明，体重过轻造成的疾病负担最大，提示需在政策层面强化综合性营养与健康干预。研究方法学上具有高度系统性和量化精度，但仍可能受到低中收入国家数据质量差异的限制。

---

## 11. 对药物难治性癫痫患者突发意外死亡理解的最新进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41285146)
**期刊：** The Lancet. Neurology
**PMID：** 41285146
**DOI：** 10.1016/S1474-4422(25)00423-5

### 第一部分 原文与翻译

**英文原标题：** Advances in understanding sudden unexpected death in people with drug-resistant epilepsy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该研究关注药物难治性癫痫患者中突发意外死亡（SUDEP）的最新机制与理解进展，表明这是临床神经医学与癫痫防治领域的重要研究方向。尽管摘要缺失，但从标题看，该工作可能综述了近期在病理生理机制、风险预测及预防策略方面的突破。此类综述有助于深化临床对SUDEP风险因素的认识，同时指出未来需要更多前瞻性研究以优化风险评估与干预方法。

---

## 12. 难治性局灶性癫痫中与癫痫发作相关的猝死（SUDEP）生物标志物（REPOMSE）：一项前瞻性多中心病例对照研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41285145)
**期刊：** The Lancet. Neurology
**PMID：** 41285145
**DOI：** 10.1016/S1474-4422(25)00379-5

### 第一部分 原文与翻译

**英文原标题：** Seizure-related biomarkers of sudden unexpected death in epilepsy (SUDEP) in drug-resistant focal epilepsy (REPOMSE): a prospective, multicentre case-control study.

> **英文摘要：**
> BACKGROUND: Novel biomarkers of the risk of sudden unexpected death in epilepsy (SUDEP) are needed to better inform people with epilepsy of their individual risk and identify those at a high risk. The aim of this study was to identify such biomarkers, particularly with the exploration of seizures characteristics that have not been previously investigated, including peri-ictal peripheral oxygen saturation (SpO) and site of seizure onset.
> 
> METHODS: We conducted a nested case-control study of SUDEP within a dedicated nationwide prospective cohort. Eligible participants were adults with drug-resistant focal epilepsy undergoing in-hospital seizure monitoring at 16 epilepsy monitoring units in France. Clinical data, results from presurgical investigations, and raw recordings from video EEG, electrocardiogram (ECG), and SpO were collected until the end of the recruitment period. The French National Directory of Natural Persons Identification was queried annually to identify deaths. SUDEP cases were adjudicated on the basis of medical records and interviews documenting the circumstances of death. Each SUDEP case was matched to four controls on the basis of study centre and date of inclusion. SUDEP risk factors were identified using LASSO-penalised conditional logistic regression.
> 
> FINDINGS: From May 18, 2010, to Aug 23, 2015, we enrolled a total of 1074 participants and followed their vital status until the end of 2018, yielding a total of 6828 patient-years of follow-up. 42 participants died during follow-up, including 18 cases of definite or probable SUDEP, resulting in a SUDEP rate of 2·64/1000 patient-years (95% CI 1·36-3·92). Four risk factors were significantly associated with the risk of SUDEP: an extratemporal epileptogenic zone (OR 37·8, 95% CI 3·21-446·2, p=0·0039), a BMI of 30 or higher (26·0, 2·0-339·6, p=0·013), male sex (12·6, 1·5-106·8, p=0·0201), and predominantly nocturnal seizures (6·0, 1·2-28·7, p=0·026). In contrast, the presence of peri-ictal SpO of less than 80% during focal seizures, the frequency of focal-to-bilateral tonic-clonic seizures, heart rate variability, age at epilepsy onset, number of antiseizure medications, and history of depression were not significantly associated with SUDEP.
> 
> INTERPRETATION: Extratemporal epilepsies involving the perisylvian region or frontal lobe appear to be associated with an increased risk of SUDEP. This finding warrants confirmation in larger cohorts and underscores the need to improve the diagnosis and surgical management of extratemporal epilepsies, which might contribute to improved SUDEP risk stratification and prevention.
> 
> FUNDING: French Ministry of Health (Programme Hospitalier de Recherche Clinique National 2009).

> **中文摘要：**
> 背景：需要新的猝死于癫痫（SUDEP）风险生物标志物，以便更好地为癫痫患者提供个体化风险信息，并识别出高危人群。本研究的目标是确定此类生物标志物，特别关注此前尚未研究的癫痫发作特征，包括发作期外周血氧饱和度（SpO）和发作起始部位。
> 
> 方法：我们在一个专门建立的全国性前瞻性队列中开展了嵌套病例对照研究。符合条件的参与者为在法国16个癫痫监测中心接受住院发作监测的成人难治性局灶性癫痫患者。我们在招募期结束前收集了临床资料、术前检查结果，以及视频脑电图（EEG）、心电图（ECG）和SpO的原始记录。每年通过法国国家自然人身份目录查询死亡信息。SUDEP病例的判定依据病历和访谈，记录死亡相关情况。每个SUDEP病例按研究中心和纳入日期匹配四个对照。SUDEP风险因素通过LASSO惩罚条件Logistic回归模型识别。
> 
> 结果：2010年5月18日至2015年8月23日期间，共纳入1074名参与者，并随访至2018年底，总随访时间为6828人年。在随访期间共有42例死亡，其中18例为确诊或可能的SUDEP，SUDEP发生率为每千人年2.64例（95% CI 1.36–3.92）。四个风险因素与SUDEP风险显著相关：颞外癫痫致痫区（OR 37.8，95% CI 3.21–446.2，p=0.0039）、BMI≥30（OR 26.0，95% CI 2.0–339.6，p=0.013）、男性（OR 12.6，95% CI 1.5–106.8，p=0.0201）以及以夜间发作为主（OR 6.0，95% CI 1.2–28.7，p=0.026）。相比之下，局灶性发作期间发作期SpO低于80%、局灶至双侧强直-阵挛性发作频率、心率变异性、癫痫起病年龄、抗癫痫药物数量及抑郁病史与SUDEP无显著关联。
> 
> 解释：涉及外侧裂周或额叶区域的颞外癫痫似乎与SUDEP风险增加相关。该发现需在更大样本中验证，并强调优化颞外癫痫的诊断与外科管理的重要性，这可能有助于改进SUDEP风险分层和预防。
> 
> 资助：法国卫生部（2009年国家临床医院研究项目）。

### 第二部分 AI 大师评价

本研究基于全国性前瞻性队列，采用嵌套病例对照设计，探索难治性局灶性癫痫中与SUDEP风险相关的发作特征及生物标志物。结果揭示颞外致痫区、高BMI、男性及夜间发作与SUDEP风险显著相关，而发作期低氧饱和度等因素并未显示关联。研究创新性在于首次提出颞外癫痫（特别是外侧裂周与额叶区域）可能的解剖学易感性。尽管样本量限制了结论的外推性，但为临床风险评估与外科干预提供了新的方向。

---

## 13. 神经发育障碍个体唾液流涎外科治疗的长期结局：一项回顾性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40962107)
**期刊：** The Journal of pediatrics
**PMID：** 40962107
**DOI：** 10.1016/j.jpeds.2025.114807

### 第一部分 原文与翻译

**英文原标题：** Long-Term Outcomes of Surgical Drooling Treatment in Individuals with Neurodevelopmental Disabilities: A Retrospective Cohort Study.

> **英文摘要：**
> OBJECTIVE: To compare the long-term treatment outcomes of submandibular duct relocation (SMDR), submandibular gland excision (SMGE), and submandibular duct ligation (SDL) for the treatment of anterior drooling in individuals with neurodevelopmental disabilities.
> 
> STUDY DESIGN: A retrospective cohort study was conducted with patients from the Netherlands who received surgery for drooling. All participants received follow-up after 8 and 32 weeks. A questionnaire was completed at least 1 year postsurgery for long-term follow-up. Visual analog scale (VAS) for drooling was the primary outcome. Secondary outcomes included the Drooling Quotient and the Drooling Severity and Frequency Scale. Repeated measures ANOVA was employed to assess the outcomes within and between each type of surgery.
> 
> RESULTS: A total of 255 patients who visited the Saliva Control Clinic between 2000 and 2021 were included in this study. For the VAS at long-term follow-up, a mean reduction was observed of 44.9 points for SMDR (P < .001), 27.2 for SMGE (P < .001), and 25.4 for SDL (P < .001). VAS increased by within-surgery difference at long-term compared with 32 weeks for SMGE (8.6, P = .036) and SDL (8.5, P = .047), but not for SMDR (2.9, P = .46). When comparing the three types of surgery, the outcomes after SMDR remained stable in the long term, while the VAS increased for SMGE (mean difference 18.9, P = .011) and SDL (mean difference 18.5, P = .013).
> 
> CONCLUSIONS: VAS for drooling, Drooling Quotient, and Drooling Severity Frequency Scale decreased after all surgical procedures. SMDR showed superior outcomes over SMGE and SDL in the long term. Our data suggest partial recurrence of drooling after SDL and SMGE.

> **中文摘要：**
> 研究目的：比较神经发育障碍个体中，针对前部流涎治疗的三种外科方式——下颌下导管重新定位术（SMDR）、下颌下腺切除术（SMGE）以及下颌下导管结扎术（SDL）——的长期治疗结局。
> 
> 研究设计：本研究为回顾性队列研究，纳入来自荷兰接受流涎手术的患者。所有受试者在术后8周和32周接受随访，术后至少1年填写问卷以评估长期随访结果。流涎视觉模拟评分（VAS）为主要结局指标，次要结局包括流涎定量指数（Drooling Quotient）和流涎严重度及频率量表（Drooling Severity and Frequency Scale）。采用重复测量方差分析（ANOVA）评估不同手术类型内及其间的变化。
> 
> 结果：共有255例在2000年至2021年期间就诊于唾液控制诊所的患者纳入研究。长期随访时，VAS平均降低分别为SMDR 44.9分（P < .001）、SMGE 27.2分（P < .001）和SDL 25.4分（P < .001）。与术后32周相比，长期随访中SMGE（8.6，P = .036）和SDL（8.5，P = .047）VAS评分有所升高，而SMDR无显著变化（2.9，P = .46）。三种手术间比较显示，SMDR的长期结局保持稳定，而SMGE（平均差值18.9，P = .011）和SDL（平均差值18.5，P = .013）的VAS评分随时间增加。
> 
> 结论：所有手术均可显著降低VAS评分、流涎定量指数及流涎严重度和频率量表评分。长期而言，SMDR较SMGE和SDL具有更优结局。研究结果提示SMGE与SDL术后可能存在流涎部分复发。

### 第二部分 AI 大师评价

该研究回顾性比较了三种常用于神经发育障碍患者流涎控制的外科方式的长期疗效。结果显示，三种手术均能有效降低流涎程度，但下颌下导管重新定位术（SMDR）的长期效果最为稳定和显著。相较之下，下颌下腺切除术与导管结扎术在长期随访中出现一定的疗效回退。研究设计严谨，随访期较长，但由于为回顾性研究，仍需前瞻性随机对照试验验证其结论的稳健性。

---

速递结束，祝您工作愉快！